| Aug 1 |
Neurocrine Biosciences Non-GAAP EPS of $1.63 beats by $0.10, revenue of $580M beats by $33.4M
|
| Aug 1 |
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
|
| Jul 31 |
Neurocrine Biosciences Q2 2024 Earnings Preview
|
| Jul 31 |
Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
|
| Jul 25 |
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
| Jul 18 |
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
|
| Jul 12 |
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
|
| Jul 11 |
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
|
| Jul 11 |
Neurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In Biotech
|
| Jul 10 |
Top Medical Stocks to Buy for Growth & Performance
|
